Surface-derivatized Nanoceria with Human Carbonic Anhydrase II Inhibitors and Fluorophores: A Potential Drug Delivery Device
RFT-263
This invention describes cerium oxide nanoparticles (nanoceria) as a potential drug delivery vehicle for treatment of the eye disease glaucoma.
While it is known that only a small amount of active medicines manage to penetrate the cornea to treat eye infections, this invention combines nanoceria with hCAII (a compound that blocks the activity of an enzyme believed to play a central role in glaucoma) to form a molecule that is exactly the right size and shape to get through and penetrate into the eye.
The disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks an enzyme that produces carbon dioxide.
Downloads
File: rft-263.pdf
Inquiries
Joy Goswami
Licensing Associate
NDSU Research Foundation
Fargo, North Dakota
(701) 231-7886 Work
(701) 231-6661 Fax
Email: jaideepgoswami@ndsurf.org